A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 824393 (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Adverse reactions; Therapeutic Use

Most Recent Events

14 Mar 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
14 Mar 2011 Planned End Date changed from 1 Jun 2013 to 1 Dec 2010 as reported by ClinicalTrials.gov.
09 Nov 2010 Planned end date changed from 1 Jan 2013 to 1 Jun 2013, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight